The sarco/endoplasmic reticulum (SR/ER) calcium (Ca2+)-ATPase (SERCA) pump is a key regulator of intracellular Ca2+ homeostasis and subsequently essential for cell survival and function [1,2]. Neurons are no exception to this; intricate pathways involving SERCA-mediated Ca2+ signaling are implicated in brain pathophysiology. Several studies have indicated that dysregulation of SERCA pumps may be involved in the molecular mechanisms underlying debilitating brain diseases including Alzheimer’s and Parkinson’s diseases, schizophrenia, bipolar disorder, ischemia and alcoholism [1-3]. Thus, this family of P-type ATPases comprises an emerging molecular target for developing efficient pharmacotherapies. Interestingly, preclinical studies in rodents suggest that chronic pharmacological activation of SERCA2 by the quinoline derivative CDN1163 comprises a potential pharmacotherapeutic target in Alzheimer’s and Parkinson’s diseases [4-6]. As little is known about the behavioral and neurochemical consequences of CDN1163 administration, in this study we investigated the potential effects of both acute and chronic pharmacological SERCA stimulation on the behavior and monoaminergic neurotransmission of naïve C57BL/6J mice of both sexes .
Britzolaki, Aikaterini, "Chronic Administration of the Novel SERCA2 Activator CDN1163 Induces Behavioral andNeurochemical Effects in Mice" (2021). Graduate Student Showcase. 6.